GLPwatch
[Successful treatment of KCNJ11 neonatal diabetes without insulin].
Ugeskr Laeger · 2018
Last updated 2026-05-28A 40-year-old man with a genetic form of diabetes (KCNJ11 mutation) was treated with high doses of glibenclamide and the GLP-1 drug liraglutide. After starting this combination, he no longer needed insulin, and his blood sugar control (measured by glycated haemoglobin) remained between 6.5% and 7.1% for the first nine months.
AI summary of the abstract below.
| Journal | Ugeskr Laeger, 2018 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.04 |
| NIH percentile | 4 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).
Verbatim abstract via PubMed 30417822 ↗